CJC-1295 DAC is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease. CJC-1295 DAC is not fda-approved. development discontinued post-phase ii. wada banned. available as research peptide. As with any research compound, individual responses vary.
Is CJC-1295 DAC Safe?
Safety is the most important consideration with any research compound. CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life with a safety profile established through preclinical research.
Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
What Are the Known Side Effects of CJC-1295 DAC?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
These effects are based on preclinical data and community reports at standard dosages of 1-2 mg per injection. Higher doses generally increase both the likelihood and severity of side effects.
Are CJC-1295 DAC Side Effects Dose-Dependent?
Most reported CJC-1295 DAC side effects are dose-dependent — meaning they're more likely at higher doses and less likely at the lower end of the 1-2 mg per injection range.
This is why starting at the minimum effective dose and titrating up is the standard approach. With a half-life of 6-8 days, any adverse effects will typically resolve within a few half-life periods after discontinuation.
What About Long-Term CJC-1295 DAC Use?
Long-term safety data for CJC-1295 DAC is limited, as with most research peptides. Standard cycles run 12-16 weeks.
CJC-1295 DAC is not fda-approved. development discontinued post-phase ii. wada banned. available as research peptide. Extended use beyond recommended cycles should be approached with caution.
Does CJC-1295 DAC Interact With Other Compounds?
Synergizes with GHRP-6 or GHRP-2 for amplified GH pulse amplitude. The sustained release makes it less ideal for stacking than CJC-1295 no DAC, which preserves natural pulsatility.
When stacking peptides, be aware that combining multiple compounds increases the total side-effect surface area. Monitor closely when introducing any new compound.
How Can You Minimize CJC-1295 DAC Side Effects?
Start at the lower end of the dosage range (1-2 mg per injection). Use proper reconstitution and injection technique to minimize injection site reactions. Store correctly (lyophilized at -20°C, reconstituted at 2-8°C) to maintain purity.
Source only from vendors with third-party COA testing — contaminated or mislabeled products are a significant source of unexpected adverse effects.
What Is the Bottom Line on CJC-1295 DAC Safety?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease. Overall, CJC-1295 DAC is considered a compound requiring careful monitoring at standard research doses.
Read our CJC-1295 DAC dosage guide for protocols designed to minimize risk.
Complete Guide
CJC-1295 DAC : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 DAC Dosage Guide
- CJC-1295 DAC Benefits
- CJC-1295 DAC Stacking Guide
- CJC-1295 DAC Cycle Guide
- CJC-1295 DAC Research
- CJC-1295 Complete Guide
Calculate Your CJC-1295 DAC Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295 DAC.
Open Calculator →Research-Grade Sourcing
If you're going to research CJC-1295 DAC, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295 DAC?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life. Synthetic GHRH analog with four amino acid substitutions conjugated to a drug affinity complex that binds endogenous albumin. It is researched for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
What is the recommended CJC-1295 DAC dosage?
Common dosages: 1-2 mg per injection administered once or twice weekly via subcutaneous injection. Cycle length: 12-16 weeks. Half-life: 6-8 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295 DAC?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
Is CJC-1295 DAC safe?
CJC-1295 DAC has shown a preliminary safety profile in research. Not FDA-approved. Development discontinued post-Phase II. WADA banned. Available as research peptide. All research should follow appropriate safety protocols.